In a multicenter clinical trial, chidamide monotherapy achieved a remarkable objective response rate (ORR) of 39% in 256 relapsed/refractory peripheral T-cell lymphoma (PTCL) patients, confirming the clinical efficacy of HDAC inhibitors in this disease [18]. Here, HDAC9 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.